Related references
Note: Only part of the references are listed.The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
Francesca Ligorio et al.
CANCERS (2021)
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti et al.
EUROPEAN JOURNAL OF CANCER (2021)
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Giovanni Fuca et al.
BRITISH JOURNAL OF CANCER (2020)
Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis
Feng Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma
Donatella Iacono et al.
MELANOMA RESEARCH (2019)
Platelet count correlates with stage and predicts survival in melanoma
Saleh Rachidi et al.
PLATELETS (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O. Michielin et al.
ANNALS OF ONCOLOGY (2019)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long et al.
ANNALS OF ONCOLOGY (2019)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fuca et al.
ESMO OPEN (2019)
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors
Pawel Teterycz et al.
MELANOMA RESEARCH (2018)
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Samuel Rosner et al.
CANCER MEDICINE (2018)
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
Veronica Huber et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab (vol 27, pg 732, 2016)
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2018)
Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients
Jarrett J. Failing et al.
MELANOMA RESEARCH (2017)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Michael Hoelzel et al.
TRENDS IN IMMUNOLOGY (2016)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
Current Staging and Prognostic Factors in Melanoma
Edmund K. Bartlett et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Kristina M. Ilieva et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Platelets guide the formation of early metastatic niches
Myriam Labelle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Tumor-Initiated Inflammation Overrides Protective Adaptive Immunity in an Induced Melanoma Model in Mice
Saidi M. Soudja et al.
CANCER RESEARCH (2010)
Share Paper
